A Study of the Efficacy and Safety of Pregabalin for the Treatment of Fibromyalgia
2021年1月21日 更新者:Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
A 13-week, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Trial of Pregabalin (BID) in Patients With Fibromyalgia
The purpose of this study is to evaluate the efficacy and safety of pregabalin versus placebo for the symptomatic relief of pain associated with fibromyalgia.
If this objective is met, then the second objective will be to evaluate the efficacy and safety of pregabalin versus placebo for the management of fibromyalgia (pain, patient global assessment, and functional status).
Additionally, the study will evaluate the efficacy of pregabalin versus placebo to improve sleep, fatigue, and mood disturbance associated with fibromyalgia.
研究概览
研究类型
介入性
注册 (实际的)
751
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35294
- Pfizer Investigational Site
-
Huntsville、Alabama、美国、35801
- Pfizer Investigational Site
-
-
Arizona
-
Paradise Valley、Arizona、美国、85253
- Pfizer Investigational Site
-
Phoenix、Arizona、美国、85032
- Pfizer Investigational Site
-
Phoenix、Arizona、美国、85023
- Pfizer Investigational Site
-
Scottsdale、Arizona、美国、85254
- Pfizer Investigational Site
-
-
Arkansas
-
Hot Springs、Arkansas、美国、71913
- Pfizer Investigational Site
-
Little Rock、Arkansas、美国、72205
- Pfizer Investigational Site
-
-
California
-
Beverly Hills、California、美国、90211
- Pfizer Investigational Site
-
Long Beach、California、美国、90806
- Pfizer Investigational Site
-
Los Alamitos、California、美国、90720
- Pfizer Investigational Site
-
Newport Beach、California、美国、92660
- Pfizer Investigational Site
-
Northridge、California、美国、91324-4625
- Pfizer Investigational Site
-
Northridge、California、美国、91335
- Pfizer Investigational Site
-
Pismo Beach、California、美国、93449
- Pfizer Investigational Site
-
Redondo Beach、California、美国、90277
- Pfizer Investigational Site
-
Riverside、California、美国、92506
- Pfizer Investigational Site
-
Riverside、California、美国、92501
- Pfizer Investigational Site
-
Walnut Creek、California、美国、94598
- Pfizer Investigational Site
-
Whittier、California、美国、90601
- Pfizer Investigational Site
-
-
Connecticut
-
Danbury、Connecticut、美国、06810
- Pfizer Investigational Site
-
New Milford、Connecticut、美国、06776
- Pfizer Investigational Site
-
Stratford、Connecticut、美国、06615
- Pfizer Investigational Site
-
-
Florida
-
Clearwater、Florida、美国、33761
- Pfizer Investigational Site
-
Miami、Florida、美国、33173
- Pfizer Investigational Site
-
Ocala、Florida、美国、34474
- Pfizer Investigational Site
-
Palm Beach Gardens、Florida、美国、33410
- Pfizer Investigational Site
-
Plantation、Florida、美国、33324
- Pfizer Investigational Site
-
Plantation、Florida、美国、33317
- Pfizer Investigational Site
-
Saint Petersburg、Florida、美国、33710
- Pfizer Investigational Site
-
Saint Petersburg、Florida、美国、33709
- Pfizer Investigational Site
-
Saint Petersburg、Florida、美国、33703
- Pfizer Investigational Site
-
Sunrise、Florida、美国、33351-6637
- Pfizer Investigational Site
-
West Palm Beach、Florida、美国、33409
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta、Georgia、美国、30342
- Pfizer Investigational Site
-
Atlanta、Georgia、美国、30328
- Pfizer Investigational Site
-
Decatur、Georgia、美国、30033-5930
- Pfizer Investigational Site
-
-
Idaho
-
Boise、Idaho、美国、83704
- Pfizer Investigational Site
-
-
Illinois
-
Chicago、Illinois、美国、60610
- Pfizer Investigational Site
-
Maywood、Illinois、美国、60153
- Pfizer Investigational Site
-
Oak Brook、Illinois、美国、60523
- Pfizer Investigational Site
-
Peoria、Illinois、美国、61614
- Pfizer Investigational Site
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- Pfizer Investigational Site
-
Overland Park、Kansas、美国、66215
- Pfizer Investigational Site
-
Overland Park、Kansas、美国、66210
- Pfizer Investigational Site
-
-
Kentucky
-
Madisonville、Kentucky、美国、42431
- Pfizer Investigational Site
-
-
Louisiana
-
New Orleans、Louisiana、美国、70114
- Pfizer Investigational Site
-
-
Massachusetts
-
Newton、Massachusetts、美国、02462
- Pfizer Investigational Site
-
-
Michigan
-
East Lansing、Michigan、美国、48823
- Pfizer Investigational Site
-
Kalamazoo、Michigan、美国、49009
- Pfizer Investigational Site
-
Lansing、Michigan、美国、48917
- Pfizer Investigational Site
-
-
Missouri
-
Kansas City、Missouri、美国、64114
- Pfizer Investigational Site
-
-
New Hampshire
-
Lebanon、New Hampshire、美国、03766
- Pfizer Investigational Site
-
-
New Jersey
-
Princeton、New Jersey、美国、08540
- Pfizer Investigational Site
-
-
New York
-
Albany、New York、美国、12205
- Pfizer Investigational Site
-
New York、New York、美国、10003
- Pfizer Investigational Site
-
Rochester、New York、美国、14618
- Pfizer Investigational Site
-
-
North Carolina
-
Charlotte、North Carolina、美国、28210
- Pfizer Investigational Site
-
Wilmington、North Carolina、美国、28403
- Pfizer Investigational Site
-
Wilmington、North Carolina、美国、28401
- Pfizer Investigational Site
-
Winston-Salem、North Carolina、美国、27103
- Pfizer Investigational Site
-
-
Ohio
-
Cincinnati、Ohio、美国、45219
- Pfizer Investigational Site
-
Columbus、Ohio、美国、43212
- Pfizer Investigational Site
-
Columbus、Ohio、美国、43124
- Pfizer Investigational Site
-
Mogadore、Ohio、美国、44260
- Pfizer Investigational Site
-
Toledo、Ohio、美国、43623
- Pfizer Investigational Site
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73109
- Pfizer Investigational Site
-
-
Oregon
-
Eugene、Oregon、美国、97401
- Pfizer Investigational Site
-
Medford、Oregon、美国、97504
- Pfizer Investigational Site
-
Portland、Oregon、美国、97201
- Pfizer Investigational Site
-
-
Pennsylvania
-
Altoona、Pennsylvania、美国、16602
- Pfizer Investigational Site
-
Altoona、Pennsylvania、美国、16601
- Pfizer Investigational Site
-
Duncansville、Pennsylvania、美国、16635
- Pfizer Investigational Site
-
Johnstown、Pennsylvania、美国、15904
- Pfizer Investigational Site
-
Mechanicsburg、Pennsylvania、美国、17055
- Pfizer Investigational Site
-
Philadelphia、Pennsylvania、美国、19146
- Pfizer Investigational Site
-
Philadelphia、Pennsylvania、美国、19115
- Pfizer Investigational Site
-
Pittsburgh、Pennsylvania、美国、15213
- Pfizer Investigational Site
-
Pittsburgh、Pennsylvania、美国、15224
- Pfizer Investigational Site
-
Pittsburgh、Pennsylvania、美国、15218
- Pfizer Investigational Site
-
Pottstown、Pennsylvania、美国、19610
- Pfizer Investigational Site
-
West Reading、Pennsylvania、美国、19611-1124
- Pfizer Investigational Site
-
Wyomissing、Pennsylvania、美国、19610
- Pfizer Investigational Site
-
-
South Carolina
-
Anderson、South Carolina、美国、29621
- Pfizer Investigational Site
-
Charleston、South Carolina、美国、29406
- Pfizer Investigational Site
-
Greer、South Carolina、美国、29651
- Pfizer Investigational Site
-
-
Tennessee
-
Memphis、Tennessee、美国、38119
- Pfizer Investigational Site
-
Memphis、Tennessee、美国、38104
- Pfizer Investigational Site
-
Nashville、Tennessee、美国、37203
- Pfizer Investigational Site
-
-
Texas
-
Austin、Texas、美国、78705
- Pfizer Investigational Site
-
Dallas、Texas、美国、75246
- Pfizer Investigational Site
-
Lubbock、Texas、美国、79424
- Pfizer Investigational Site
-
Richardson、Texas、美国、75080
- Pfizer Investigational Site
-
San Antonio、Texas、美国、78229
- Pfizer Investigational Site
-
San Antonio、Texas、美国、78229-4540
- Pfizer Investigational Site
-
-
Utah
-
Salt Lake City、Utah、美国、84102
- Pfizer Investigational Site
-
-
Vermont
-
Woodstock、Vermont、美国、05091
- Pfizer Investigational Site
-
Woodstock、Vermont、美国、05091-0437
- Pfizer Investigational Site
-
-
Virginia
-
Virginia Beach、Virginia、美国、23454
- Pfizer Investigational Site
-
-
Washington
-
Seattle、Washington、美国、98104
- Pfizer Investigational Site
-
Seattle、Washington、美国、98122
- Pfizer Investigational Site
-
Yakima、Washington、美国、98902
- Pfizer Investigational Site
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 及以上 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Patients who met the American College of Rheumatology (ACR) criteria for fibromyalgia (ie, widespread pain present for at least 3 months, and pain in at least 11 of 18 specific tender point sites)
- Patients who completed at least 4 pain diaries within the last 7 days and the average pain score must have been ≥4, and had a score of ≥40 mm on the Visual Analogue Scale (VAS) of the SF-MPQ at screening (Visit 1) and randomization (Visit 2)
Exclusion Criteria:
- Patients with other severe pain that may confound assessment or self-evaluation of the pain associated with fibromyalgia
- Patients with any inflammatory muscle or rheumatologic disease other than fibromyalgia, active infections, or untreated endocrine disorders
- Patients with severe depression
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:一个
|
Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
|
|
实验性的:乙
|
Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
|
|
实验性的:C
|
Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
|
|
安慰剂比较:丁
|
Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Endpoint mean pain score derived from the subject's daily pain diary
大体时间:Endpoint
|
Endpoint
|
|
Patient Global Assessment (Patient Global Impression of Change) at Termination Visit
大体时间:Weeks 5 and 13
|
Weeks 5 and 13
|
|
Change from baseline in functioning (score created from the Short Form-36 [SF-36] Social and Physical Functioning, Fibromyalgia Impact Questionnaire [FIQ]-Total Score, and Sheehan Disability Scale [SDS] Total Score) at Termination Visit
大体时间:Baseline and Weeks 5, 9, and 13
|
Baseline and Weeks 5, 9, and 13
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
Change from baseline in FIQ scores at Weeks 5, 9, and 13
大体时间:Baseline and Weeks 5, 9, and 13
|
Baseline and Weeks 5, 9, and 13
|
|
Change from baseline in SDS scores at Weeks 5, 9, and 13
大体时间:Baseline and Weeks 5, 9, and 13
|
Baseline and Weeks 5, 9, and 13
|
|
Change from baseline in Medical Outcomes Study (MOS)-Sleep Scale scores at Weeks 5, 9, and 13
大体时间:Baseline and Weeks 5, 9, and 13
|
Baseline and Weeks 5, 9, and 13
|
|
Quality of Sleep Score from the Daily Sleep Diary
大体时间:Daily
|
Daily
|
|
Change from baseline in Multidimensional Assessment of Fatigue (MAF) scores at Weeks 5, 9, and 13
大体时间:Baseline and Weeks 5, 9, and 13
|
Baseline and Weeks 5, 9, and 13
|
|
Change from baseline in Hospital Anxiety and Depression Scale (HADS) scores at Week 13
大体时间:Baseline and Week 13
|
Baseline and Week 13
|
|
Change from baseline in Short Form McGill Pain Questionnaire (SF-MPQ) scores at Weeks 5, 9, and 13
大体时间:Screening, baseline, and Weeks 5, 9, and 13
|
Screening, baseline, and Weeks 5, 9, and 13
|
|
Change from baseline in Fibromyalgia Health Assessment Questionnaire (F-HAQ) scores at Weeks 9 and 13
大体时间:Baseline and Weeks 9 and 13
|
Baseline and Weeks 9 and 13
|
|
Adverse events
大体时间:Weeks 1, 2, 5, 9, 13, and at follow-up
|
Weeks 1, 2, 5, 9, 13, and at follow-up
|
|
Physical examination, including vital signs and weight
大体时间:Baseline and Week 5 (vital signs only) and 13
|
Baseline and Week 5 (vital signs only) and 13
|
|
Neurological examination
大体时间:Screening and Week 13
|
Screening and Week 13
|
|
Electrocardiogram
大体时间:Screening and Week 13
|
Screening and Week 13
|
|
Laboratory tests, including chemistry and hematology
大体时间:Baseline and Weeks 5, 13, and at follow-up
|
Baseline and Weeks 5, 13, and at follow-up
|
|
Urinalysis
大体时间:Baseline and Weeks 13 and at follow-up
|
Baseline and Weeks 13 and at follow-up
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Clair A, Emir B. The safety and efficacy of pregabalin for treating subjects with fibromyalgia and moderate or severe baseline widespread pain. Curr Med Res Opin. 2016;32(3):601-9. doi: 10.1185/03007995.2015.1134463. Epub 2016 Jan 27.
- Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, McQuay HJ. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskelet Disord. 2011 Jun 3;12:125. doi: 10.1186/1471-2474-12-125.
- Bhadra P, Petersel D. Medical conditions in fibromyalgia patients and their relationship to pregabalin efficacy: pooled analysis of Phase III clinical trials. Expert Opin Pharmacother. 2010 Dec;11(17):2805-12. doi: 10.1517/14656566.2010.525217. Epub 2010 Nov 2.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2004年9月1日
研究完成 (实际的)
2005年6月1日
研究注册日期
首次提交
2008年3月25日
首先提交符合 QC 标准的
2008年3月25日
首次发布 (估计)
2008年3月27日
研究记录更新
最后更新发布 (实际的)
2021年1月25日
上次提交的符合 QC 标准的更新
2021年1月21日
最后验证
2008年4月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.